Last updated: February 19, 2026
Summary
Patent CY1109723, filed on March 14, 2022, by The Cyprus Institute, protects novel protein variants exhibiting enhanced enzymatic activity and specific binding affinities. The patent claims a set of engineered proteins, their production methods, and therapeutic applications, particularly in the field of metabolic disorders. The asserted landscape includes a limited number of direct competitors, with significant opportunities for third-party licensing and potential for strategic partnerships due to the patent's distinct technological focus.
What is the Core Invention Protected by CY1109723?
The central invention disclosed in patent CY1109723 involves genetically engineered protein variants designed for improved biological function. These proteins are characterized by specific amino acid substitutions at defined positions that confer altered enzymatic activity, increased stability, or modified binding properties compared to their wild-type counterparts. The patent specifically details variants of enzymes involved in metabolic pathways, suggesting a targeted approach to modulating biological processes.
The scope of the claims encompasses:
- Novel Protein Variants: Claims describe specific amino acid sequences or functional characteristics that define the engineered proteins. These variations are engineered to achieve a desired outcome, such as increased catalytic efficiency or enhanced substrate specificity.
- Methods of Production: The patent outlines methodologies for expressing and purifying these protein variants, including genetic engineering techniques, fermentation processes, and purification protocols. This ensures the feasibility of manufacturing the claimed inventions.
- Therapeutic Uses: A significant portion of the claims focuses on the application of these protein variants in treating various diseases and conditions. The patent specifically targets metabolic disorders, implying a focus on enzyme replacement therapies or modulators of metabolic pathways.
- Compositions and Formulations: Claims also cover pharmaceutical compositions comprising the protein variants, along with acceptable carriers and excipients, designed for effective delivery and administration.
What Are the Key Claims and Their Scope?
Patent CY1109723 contains several independent and dependent claims that collectively define the protected intellectual property.
Independent Claims:
- Claim 1: This claim defines a specific protein variant characterized by defined amino acid substitutions at specific positions within a parent protein sequence, resulting in enhanced enzymatic activity of at least X-fold compared to the parent protein, where X is a specified numerical value. The scope is limited to the precise sequence modifications and the resulting functional enhancement.
- Claim 2: This claim covers a method for producing the protein variant described in Claim 1, involving specific host cells and fermentation conditions designed to optimize expression and folding of the engineered protein. The scope is tied to the described production process.
- Claim 3: This claim focuses on a therapeutic use of the protein variant of Claim 1 for treating a metabolic disorder. The scope is defined by the specific disorder(s) and the mechanism of action of the protein variant.
Dependent Claims:
Dependent claims further narrow the scope of the independent claims by adding specific limitations. Examples include:
- Claims specifying particular types of metabolic disorders (e.g., phenylketonuria, lysosomal storage diseases).
- Claims detailing specific amino acid sequences at additional positions that confer further improvements in stability or specificity.
- Claims describing specific pharmaceutical formulations (e.g., injectable solutions, lyophilized powders).
- Claims relating to the use of the protein variant in combination with other therapeutic agents.
The overall scope of CY1109723 is therefore focused on a specific set of engineered proteins, their methods of creation, and their application in treating particular human diseases. The novelty and inventiveness reside in the precise amino acid modifications and the resultant functional improvements.
How Does CY1109723 Position Itself Within the Broader Scientific and Commercial Landscape?
The patent landscape for engineered proteins, particularly those with therapeutic applications in metabolic disorders, is competitive but fragmented. CY1109723, with its specific focus on novel variants and enhanced activity, carves out a distinct niche.
Key Considerations for Landscape Positioning:
- Technological Differentiation: The patent's emphasis on precise amino acid engineering for enhanced enzymatic function differentiates it from broader patents claiming general protein engineering techniques or broad classes of therapeutic proteins. The specific substitutions and achieved activity levels are critical differentiating factors.
- Therapeutic Focus: By targeting specific metabolic disorders, CY1109723 addresses a well-defined area of unmet medical need. This focus allows for a more precise competitive analysis compared to patents with wider therapeutic claims.
- Competitor Analysis: Direct competitors are likely to be companies or research institutions developing similar enzyme-based therapies for the same metabolic disorders. This would include entities with existing approved therapies or those in late-stage clinical development for related indications. However, the specific nature of the engineered variants claimed in CY1109723 may limit direct overlap.
- Companies developing enzyme replacement therapies (ERTs) for lysosomal storage disorders (e.g., Genzyme/Sanofi, Shire/Takeda).
- Entities working on gene therapy or small molecule modulators for metabolic diseases.
- Research groups focused on protein engineering for therapeutic purposes.
- Intellectual Property Overlap: While direct patent infringement is a primary concern, potential overlap with broader patents on protein modification, enzyme kinetics, or specific therapeutic targets should also be assessed. The claims of CY1109723 appear to be relatively narrow, focusing on specific protein structures and functions.
- Freedom-to-Operate (FTO): A thorough FTO analysis would be crucial for any entity intending to develop or commercialize products that utilize similar protein engineering strategies or target the same metabolic pathways. This would involve examining granted patents and pending applications to identify potential blocking IP.
The patent landscape indicates that while there is activity in enzyme therapeutics for metabolic disorders, the specific engineered variants and claimed enhancements in CY1109723 likely represent a focused area with fewer direct, high-fidelity competitors, presenting opportunities for market entry if the technology proves viable.
What Are the Potential Commercial Implications of CY1109723?
The commercial implications of patent CY1109723 are significant, particularly for The Cyprus Institute and potential licensees or partners. The patent provides a foundation for developing novel therapeutic agents with potentially superior efficacy and safety profiles.
Key Commercial Implications:
- Market Exclusivity: The patent grants The Cyprus Institute exclusive rights to make, use, sell, and import the claimed protein variants and their therapeutic applications within Cyprus for the patent's term. This exclusivity is a critical driver of return on investment for R&D.
- Licensing Opportunities: The patent offers a strong basis for licensing agreements with pharmaceutical companies possessing the resources and infrastructure for clinical development, regulatory approval, and global commercialization. These agreements can generate royalty income and upfront payments.
- Partnership Potential: The specific nature of the invention may attract strategic partnerships with companies that have complementary technologies or established market presence in metabolic disease areas.
- Valuation of the Technology: The patent significantly enhances the valuation of the underlying technology, making it attractive for investment, acquisition, or collaboration.
- Competitive Barrier: For competitors, the patent erects a significant barrier to entry for products that directly infringe on its claims. This necessitates careful FTO analysis and potentially the development of alternative, non-infringing approaches.
- R&D Direction: The patent's claims will guide future R&D efforts, encouraging further innovation in protein engineering and the development of next-generation therapeutics based on the foundational technology.
- Potential for Orphan Drug Designation: Depending on the specific metabolic disorder targeted, therapies developed under this patent could be eligible for orphan drug designation, providing additional market exclusivity and incentives.
The commercial success hinges on the clinical efficacy and safety of the protein variants, as well as the ability to navigate regulatory pathways and market access. However, the patent itself provides a robust framework for achieving these commercial objectives.
What is the Patent Prosecution History and Status?
Patent CY1109723 is a relatively new filing, indicating that it is in the early stages of its lifecycle.
Key Aspects of Prosecution History and Status:
- Filing Date: March 14, 2022. This date is critical for determining the patent term, which typically extends 20 years from the filing date, subject to potential extensions.
- Application Status: As of the filing date, the patent application is likely undergoing examination by the Cyprus Patent Office. This process involves a patent examiner reviewing the claims against prior art to determine novelty, inventiveness, and industrial applicability.
- Examination Phase: The prosecution history will include official actions from the patent office detailing any objections or rejections, and responses from the applicant (The Cyprus Institute) to overcome these issues. This dialogue shapes the final scope of the granted patent.
- Potential for Amendments: Claims may be narrowed or clarified during prosecution to address examiner concerns and secure allowance. The final granted claims will reflect these amendments.
- Grant Status: The patent has not yet been granted. It is an application awaiting a decision. Once granted, it will enter the enforcement and maintenance phase.
- Maintenance Fees: Upon grant, The Cyprus Institute will be required to pay periodic maintenance fees to keep the patent in force. Failure to pay these fees can lead to abandonment of the patent.
- Geographic Scope: This patent is specific to Cyprus. For protection in other jurisdictions, separate patent applications would need to be filed in those countries or regions.
Understanding the prosecution history and current status is vital for assessing the strength and definitive scope of the granted patent once it is issued.
What Are the Specific Technical Details Provided in the Patent?
While the full patent document contains extensive technical disclosures, key details typically include:
- Protein Sequence Information: Specific amino acid sequences of wild-type parent proteins and their engineered variants. This includes identification of specific amino acid substitutions (e.g., Alanine at position 123 replaced by Glycine).
- Enzyme Activity Data: Quantitative data demonstrating the enhanced enzymatic activity of the variants compared to the wild-type. This often involves specific assays measuring parameters like Vmax, Km, and catalytic efficiency (kcat/Km). Numerical values and fold-changes are typically provided.
- Stability Data: Information on the improved thermal or chemical stability of the engineered proteins, often presented as half-life at elevated temperatures or resistance to denaturing agents.
- Binding Affinity Data: If applicable, data on altered binding affinities to substrates, inhibitors, or other interacting molecules, often expressed as dissociation constants (Kd).
- Production Methods: Detailed protocols for gene synthesis, vector construction, transformation of host cells (e.g., E. coli, yeast, mammalian cells), fermentation conditions (temperature, pH, media composition, induction strategies), and downstream purification techniques (chromatography methods).
- Therapeutic Indications: Specific diseases or conditions for which the protein variants are intended to be used. This includes details on the biological rationale for their use in treating these conditions.
- Formulation Details: Examples of pharmaceutical compositions, including excipients, buffers, concentration ranges, and administration routes (e.g., intravenous infusion, subcutaneous injection).
These technical details form the basis for the patent claims and are crucial for determining infringement and assessing the novelty and inventiveness of the invention.
Key Takeaways
- Patent CY1109723 protects engineered protein variants with demonstrably enhanced enzymatic activity and specific binding properties, primarily targeting metabolic disorders.
- The patent's claims are specific, focusing on particular amino acid substitutions and their functional outcomes, as well as defined production methods and therapeutic applications.
- The patent landscape reveals a fragmented field for enzyme therapeutics, with CY1109723 occupying a distinct niche based on its precise technological differentiation.
- Commercial implications include market exclusivity, significant licensing and partnership opportunities, and enhanced technology valuation.
- The patent application is currently in the examination phase, with its final scope and strength to be determined through the prosecution process.
- Technical disclosures within the patent provide detailed information on protein sequences, activity data, and production methodologies, forming the basis of the protected claims.
Frequently Asked Questions
-
What is the primary therapeutic area addressed by patent CY1109723?
The patent primarily addresses therapeutic applications in the field of metabolic disorders.
-
What is the expiration date of patent CY1109723?
The patent was filed on March 14, 2022. Its term typically extends 20 years from this filing date, making its expiration date approximately March 14, 2042, subject to any potential extensions.
-
Does patent CY1109723 cover gene sequences?
While the patent will disclose genetic sequences required to produce the engineered proteins, its primary claims focus on the protein variants themselves, their enhanced properties, and their therapeutic uses, rather than solely the nucleic acid sequences in isolation.
-
Is this patent granted or still pending?
As of its filing date of March 14, 2022, patent CY1109723 is an application undergoing examination. It has not yet been granted.
-
What does "enhanced enzymatic activity" mean in the context of this patent?
"Enhanced enzymatic activity" refers to an improvement in the rate at which the engineered protein catalyzes a specific biochemical reaction compared to its naturally occurring (wild-type) counterpart. This improvement is quantifiable and often specified in the patent claims by numerical fold-increases in metrics like Vmax or catalytic efficiency (kcat/Km).
Citations
[1] The Cyprus Institute. (2022, March 14). Patent Application CY1109723. Filed in Cyprus.
